These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 28303523)
1. Initiation, Switching, and Cessation of Psoriasis Treatments Among Patients with Moderate to Severe Psoriasis in the United States. Armstrong AW; Koning JW; Rowse S; Tan H; Mamolo C; Kaur M Clin Drug Investig; 2017 May; 37(5):493-501. PubMed ID: 28303523 [TBL] [Abstract][Full Text] [Related]
2. Under-Treatment of Patients with Moderate to Severe Psoriasis in the United States: Analysis of Medication Usage with Health Plan Data. Armstrong AW; Koning JW; Rowse S; Tan H; Mamolo C; Kaur M Dermatol Ther (Heidelb); 2017 Mar; 7(1):97-109. PubMed ID: 27905011 [TBL] [Abstract][Full Text] [Related]
3. Clearance of psoriasis: the impact of private versus public insurance. Buzney CD; Peterman C; Saraiya A; Au SC; Dumont N; Mansfield R; Gottlieb AB J Drugs Dermatol; 2015 Feb; 14(2):119-25. PubMed ID: 25689806 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis. Bissonnette R; Kerdel F; Naldi L; Papp K; Galindo C; Langholff W; Tang KL; Szapary P; Fakharzadeh S; Srivastava B; Goyal K; Gottlieb AB J Drugs Dermatol; 2017 Oct; 16(10):1002-1013. PubMed ID: 29036254 [TBL] [Abstract][Full Text] [Related]
5. Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study. Christophers E; Segaert S; Milligan G; Molta CT; Boggs R J Dermatolog Treat; 2013 Jun; 24(3):193-8. PubMed ID: 22620684 [TBL] [Abstract][Full Text] [Related]
6. Treatment patterns in moderate-to-severe plaque psoriasis: results from a Belgian cross-sectional study (DISCOVER). Lambert J; Ghislain PD; Lambert J; Cauwe B; Van den Enden M J Dermatolog Treat; 2017 Aug; 28(5):394-400. PubMed ID: 27791446 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center. Au SC; Madani A; Alhaddad M; Alkofide M; Gottlieb AB J Drugs Dermatol; 2013 Aug; 12(8):861-6. PubMed ID: 23986158 [TBL] [Abstract][Full Text] [Related]
8. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. Armstrong AW; Robertson AD; Wu J; Schupp C; Lebwohl MG JAMA Dermatol; 2013 Oct; 149(10):1180-5. PubMed ID: 23945732 [TBL] [Abstract][Full Text] [Related]
9. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). Strober B; Gooderham M; de Jong EMGJ; Kimball AB; Langley RG; Lakdawala N; Goyal K; Lawson F; Langholff W; Hopkins L; Fakharzadeh S; Srivastava B; Menter A J Am Acad Dermatol; 2018 Jan; 78(1):70-80. PubMed ID: 29102053 [TBL] [Abstract][Full Text] [Related]
10. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan. Feldman SR; Evans C; Russell MW J Dermatolog Treat; 2005 Feb; 16(1):37-42. PubMed ID: 15897166 [TBL] [Abstract][Full Text] [Related]
11. Treatment patterns with topicals, traditional systemics and biologics in psoriasis - a Swedish database analysis. Svedbom A; Dalén J; Mamolo C; Cappelleri JC; Petersson IF; Ståhle M J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):215-223. PubMed ID: 24813476 [TBL] [Abstract][Full Text] [Related]
12. Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis. Paller AS; Singh R; Cloutier M; Gauthier-Loiselle M; Emond B; Guérin A; Ganguli A J Drugs Dermatol; 2018 Feb; 17(2):187-194. PubMed ID: 29462227 [TBL] [Abstract][Full Text] [Related]
13. Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis. Armstrong A; Levi E J Drugs Dermatol; 2017 Dec; 16(12):1240-1245. PubMed ID: 29240859 [TBL] [Abstract][Full Text] [Related]
14. Defining and treating moderate plaque psoriasis: a dermatologist survey. Knuckles MLF; Levi E; Soung J J Dermatolog Treat; 2018 Nov; 29(7):658-663. PubMed ID: 29502473 [TBL] [Abstract][Full Text] [Related]
15. Real-World Claims Analyses of Comorbidity Burden, Treatment Pattern, Healthcare Resource Utilization, and Costs in Pediatric Psoriasis. Edson-Heredia E; Anderson S; Guo J; Zhu B; Malatestinic WN; Wine-Lee L; Swanson E Adv Ther; 2021 Jul; 38(7):3948-3961. PubMed ID: 34091866 [TBL] [Abstract][Full Text] [Related]
16. Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization. Armstrong AW; Foster SA; Comer BS; Lin CY; Malatestinic W; Burge R; Goldblum O BMC Dermatol; 2018 Jun; 18(1):4. PubMed ID: 29954363 [TBL] [Abstract][Full Text] [Related]
17. Treatment patterns and healthcare resource utilization in palmoplantar pustulosis patients in Japan: A claims database study. Miyazaki C; Sruamsiri R; Mahlich J; Jung W PLoS One; 2020; 15(5):e0232738. PubMed ID: 32442204 [TBL] [Abstract][Full Text] [Related]
18. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis. Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729 [TBL] [Abstract][Full Text] [Related]
19. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation. Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130 [TBL] [Abstract][Full Text] [Related]
20. Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis. Han C; Lofland JH; Zhao N; Schenkel B J Drugs Dermatol; 2011 Aug; 10(8):843-50. PubMed ID: 21818505 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]